The demise of a potential competitor gave Dermira investors a reason to cheer.
News & Analysis: Dermira
The company gave investors a closer look at its eczema candidate and they liked what they saw.
DERM earnings call for the period ending March 31, 2019.
Results from a mid-stage study with a potential new eczema drug gave investors a reason to cheer.
An analyst's upgrade provides another boost to the high-flying biotech stock.
The skincare specialist's experimental eczema treatment hit the mark in mid-stage testing, but what about the road ahead?
Great clinical results for its experimental atopic dermatitis drug provided a huge catalyst for Dermira.
The company hosted its 2018 analyst and investor day. It didn't go well.
Learn what kept these stocks out of the rally.
Shares collapsed to new all-time lows on disappointing product development news.